N/A N=73 Phenotyping Adherence Through Technology-Enabled Reports and Navigation
Medication Adherence
Primary: Medication Adherence — 21.6; 23.8 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=266,890 The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
Phase 2 N=54 Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
Multiple Sclerosis
Primary: Expanded Disability Status Scale (EDSS) Plus — 17; 17 Participants — p=1.0
Phase 3 N=354 Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Dyslipidemias · High Cholesterol · Hypercholesterolemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] — .25; -36.05 percent change from baseline — p=<.0001
N/A N=43 Improving Care Through Improv: Promoting Mastery in the Moment
Caregiver Burden
Primary: Pearlin Mastery, Loss, and Competence: Caregiver Competence Subscale — 11.10; 11.63; 11.93 Score on a scale
Phase 3 N=178 An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
Presbyopia
Primary: Number of Participants With Treatment Emergent Adverse Events. — 43; 16 Participants
Phase 1 N=12 Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
Bioavailability
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (Clast) (AUClast) of Nirmatrelvir — 35020; 31700; 35990…
Phase 1 N=69 Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients
Morbid Obesity · Bariatric Surgery Candidate
Primary: Mean 24 Hour Visual Analogue Scale (VAS) Pain Score — 1; 3 score on a scale
N/A N=956 Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
Tobacco Dependence
Primary: Number of Participants Who Quit Smoking at 3, 6, 12, and 18 Months — 13; 70; 63; 15 Participants
N/A N=16 Neural Underpinnings of Turning
Aging
Primary: Duration of Cortical Silent Period (CSP) (ms) — 104.34; 99.71 milliseconds (ms)
Phase 3 N=29 An Endometrial Cancer Chemoprevention Study of Metformin
Gynecology
Primary: To Evaluate the Participant Body Weight in Pounds (Lbs) — 108.57; 99.3; 101.64; 94.1 lbs — p=0.006
N/A N=731 Impact of Deep Versus Standard Muscle Relaxation on Intra-operative Safety
Neuromuscular Blockade · Rocuronium · Anesthetics
Primary: Classic Score>1 — 66; 54 participants
Phase 3 N=90 A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Atopic Dermatitis
Primary: Percentage of Participants Achieving Eczema Area and Severity Index 75 (≥75% Reduction From Baseline in EASI) at Week 16 — 69.2 percentage of participants
Phase 2 N=150 Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome
Primary: The Number of Vomiting/Retching Events Reported by Study Participants Following Treatment/Dosing During the Home Treament Period. — 0.69; 1.43; 1.33; 1.48 event — p=0.7024
N/A N=20 Evaluation of BiCROS Fitting Benefits
Unilateral Deafness
Primary: Speech Intelligibility in Noise Measured With US Matrix Test (Noise From a Defined Loudspeaker) — -8.8; -3.7; -9.2; -2.8 dBSRT